EphB4-binding peptide for dual modality {micro}PET/CT and optical imaging of glioblastoma in orthotopic xenograft models

miao huang,chiyi xiong,rui zhang,wei lu,qian huang,leo garcia flores,juri g gelovani,chun li

2011-01-01

Journal of Nuclear Medicine

Abstract:233 Objectives EphB4 receptors, a member of the largest family of receptor tyrosine kinases, are found over-expressed in a variety of tumors cells including glioma cells as well as angiogenic blood vessels. The purpose of this study was to examine whether EphB4-binding peptide TNYL-RAW labeled with both 64Cu and Cy5.5 dye could be used as a molecular imaging agent for dual-modality (PET/CT and optical) imaging of human glioma in orthotopic brain tumor models. Methods A Cy5.5 labeled EphB4-specific binding peptide TNYL-RAW was conjugated to the radiometal chelator 1, 4,7,10-tetraazadodecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) and labeled with 64Cu for in vitro binding and in vivo dual PET/CT and optical imaging studies. Tumors and brains were removed at the end of the imaging sessions for immunehistochemical staining and fluorescence microscopic examinations. Results In vitro, dual labeled TNYL-RAW displayed significantly higher binding to U251 glioma cells over-expressing EphB4 than to U87 cells that express low level of EphB4. The binding of dual labeled TNYL-RAW to U251 cells could be blocked by a large excess of unlabeled peptide. In vivo, µPET/CT and near-infrared optical imaging clearly showed the uptake of the dual labeled TNYL-RAW peptide in both U251 and U87 tumors in the brains of nude mice after intravenous injection. The specific uptake of dual labeled peptide in both tumors was confirmed by blocking experiments. In U87 tumors, Cy5.5-labeled peptide was found co-localized only with CD31- and EphB4-expressing tumor blood vessels. Conclusions Dual-labeled EphB4-specific peptide could be used as a non-invasive molecular imaging agent for PET/CT and optical imaging of glioma owing to its ability to bind to EphB4-expressing angiogenic blood vessels and to EphB4-expressing tumor cells